Background
==========

Interference with tumor vessel formation and blood supply has become a well-recognized approach of cancer therapy \[[@B1]\], as epitomized by the recent FDA approval of antiangiogenic drugs such as the humanized anti Vascular Endothelial Growth Factor (VEGF) antibody Avastin^®^\[[@B2]\]. Vascularization is required for tumor growth and metastasis, and constitutes an important step in the control of cancer progression \[[@B3]\]. Experimental evidence correlates tumor vascularization with high malignancy and poor prognosis, and shows that elevated levels of angiogenic factors, such as VEGF and basic Fibroblast Growth Factor (FGF-2), are associated with tumor progression \[[@B4]\]. Moreover, expansive growth of metastasis appears to be linked to the ability to stimulate endothelial cell growth \[[@B5]\].

Tumor-induced vessels are ultrastructurally abnormal and differ from normal vasculature. They lack functional pericytes and are unusually permeable \[[@B6]\]. These abnormalities reflect the pathological nature of their induction, and underpin the novel therapeutic strategies directed against the vascular elements of the tumor stroma to selectively affect tumor vasculature and inhibit tumor growth \[[@B7]\].

In recent years an increasing body of evidence suggests that tumor vasculature expresses unique markers that distinguish it from normal vasculature. Numerous efforts have been aimed at the molecular characterization of tumor associated endothelial cells (EC) in the search for differences between tumor and normal tissue EC. A variety of techniques have been applied to study EC *in vivo*, isolated from *ex vivo*specimens or cultured *in vitro*. The *in vivo*phage display technology was used to identify molecules selectively expressed on tumor endothelium \[[@B8],[@B9]\], while other approaches exploited the *in vivo*proteomic analysis to detect antigens accessible from the vasculature \[[@B10],[@B11]\]. These techniques have allowed, mostly through studies conducted in experimental tumor models, the identification of vascular-specific motifs expressed by different tumor types and during different stages of carcinogenesis.

Gene expression of EC isolated from *ex vivo*human cancer and normal specimens, analyzed by means of Serial Analysis of Gene Expression (SAGE) or microarray, revealed differences at the transcriptional level in tumor and normal tissues \[[@B12]-[@B15]\]. *In vitro*models have been widely used to identify the specific functions of the endothelium and to understand the molecular modifications that might occur during angiogenesis. In these studies EC were exposed to different microenvironmental conditions, such as angiogenic growth factors and matrix proteins, shear stress, hypoxia, or tumor conditioned media \[[@B16]-[@B20]\]. All of these approaches led to the identification of mechanisms and molecules that are potentially involved in the formation of blood vessels. Despite these findings, attempts to discover tumor EC markers have always been hampered by technical difficulties in isolating functionally intact and phenotypically stable EC from tumor tissues. In fact, all the *in vitro*models have used cultures of immortalized EC and/or primary EC from human umbilical vein (HUVEC).

We developed a method to isolate and culture EC from tumor specimens (TdEC), by which we were able to show that TdEC *in vitro*maintain several of the features described for tumor vasculature and that they differ from EC isolated from normal tissue (i.e., from human adrenal gland HA-EC) \[[@B21]\]. These findings suggested that TdEC and HA-EC might represent useful tools to study tumor vessel properties and, ultimately, to identify tumor vasculature markers.

Here we describe the isolation of EC from human specimens and the characterization of the transcriptional profiles of EC derived from ovarian carcinoma (HOC-EC) and HA-EC by means of microarray technology. Through the comparison of HOC-EC and HA-EC gene expression we were able to demonstrate that tumor-associated EC differ from those in normal tissues, thus proving that molecular differences are maintained *in vitro*. We successfully identified molecules that are expressed selectively by the tumor vasculature *in vivo*, thus providing distinctive features to be exploited to selectively target tumor vasculature.

Results
=======

Characterization of Endothelial Cells (EC) isolated from human specimens
------------------------------------------------------------------------

Endothelial cells were reproducibly isolated from human tissue specimens: HOC-EC from ovarian carcinoma, HKC-EC from kidney carcinoma, HA-EC from adrenal gland and HSk-EC from skin.

Before use, their endothelial origin was established. Endothelial cell cultures typically created a homogeneous monolayer of elongated cells in close contact and maintained an uniform morphology after few passages in culture; they formed capillary-like cord structures when plated on matrigel (data not shown and \[[@B21]\]). Their endothelial origin was established by positive immunostaining for platelet-endothelial cell adhesion molecule-1 (CD31/PECAM-1), von Willebrand Factor (vWF) and vascular E-cadherin (VE-cadherin) (Table [1](#T1){ref-type="table"}). In addition, no staining was observed when the cells were analyzed for the expression of alpha-Smooth Muscle Actin (alpha-SMA), a typical non-endothelial marker (Table [1](#T1){ref-type="table"}). Flow cytometry studies assessed the ability to uptake low density lipoproteins (LDL), a characteristic of endothelial cells, and confirmed the positivity for CD31/PECAM-1 (data not shown).

###### 

Typical endothelial signatures of the cells isolated from human cancer and normal tissue specimens

                      **CD31/PECAM-1**   **vWF\***   **VE-cadherin**   **alpha-SMA**
  ------------------- ------------------ ----------- ----------------- ---------------
  **HOC-EC**(n = 9)   73--98             75--99      97--100           0
  **HKC-EC**(n = 3)   85--93             27--67      nt                0
  **HA-EC**(n = 9)    94--99             30--90      99--100           0
  **HSk-EC**(n = 2)   95--97             80--99      nt                0
  **HUVEC**(n = 6)    80--99             90--99      99--100           0

Percentages of positive cells analyzed by immunohistochemistry evaluating a total of 500 cells/population. In parentheses are the number of independent human EC populations evaluated (HOC-EC = ovarian carcinoma EC; HKC-EC = kidney carcinoma EC; HA-EC = adrenal gland-EC; HSk-EC = skin-EC, HUVEC = umbilical vein EC).

Shown are the range of values obtained for the different endothelial cell types.

\* Population showing positivity values below 65% were not utilized. nt=not determined

The purity of the isolated EC was comparable to that of EC from umbilical vein (HUVEC), which were used as the reference population for EC (Table [1](#T1){ref-type="table"}).

Microarray results, performed on HA-EC and HOC-EC, confirmed the endothelial origin of the isolated cells (Table [2](#T2){ref-type="table"}). The typical endothelial genes expressed at high levels include COL8A1, COL18A1, CYR61, endoglin, E-selectin, HIF1A, ICAM-1, JAM3 junctional adhesion molecule, neuropilin-2, PAR-1 thrombin receptor, P-selectin, TEK endothelial tyrosine kinase, VEGFR-1, and VEGFR-2. Among these, the presence of transcripts for CD31/PECAM-1, VE-cadherin and vWF, whose protein expression was shown by immunohistochemical methods (Table [1](#T1){ref-type="table"}), is worth emphasizing.

###### 

Typical endothelial genes highly expressed by HOC-EC and HA-EC

  **Unigene Cluster**   **Symbol**   **Gene Name**
  --------------------- ------------ ---------------------------------------------------------------------------------
  Hs.83347              AAMP         Angio-associated, migratory cell protein
  Hs.426312             AMOTL2       Angiomotin like 2
  Hs.521731             ANGPTL2      Angiopoietin-like 2
  Hs.448589             ANKRD1       Ankyrin repeat domain 1 (cardiac muscle)
  Hs.185055             BENE         BENE protein
  Hs.495731             BMX          BMX non-receptor tyrosine kinase
  Hs.76206              CDH5         Cadherin 5, type 2, VE-cadherin (vascular epithelium)
  Hs.482562             F2R          Coagulation factor II (thrombin) receptor, PAR-1
  Hs.134830             COL8A1       Collagen, type VIII, alpha 1
  Hs.517356             COL18A1      Collagen, type XVIII, alpha 1
  Hs.410037             CTGF         Connective tissue growth factor
  Hs.8867               CYR61        Cysteine-rich, angiogenicinducer, 61
  Hs.174050             EDF1         Endothelial differentiation-related factor 1
  Hs.76753              ENG          Endoglin (Osler-Rendu-Weber syndrome 1)
  Hs.129944             ESM1         Endothelial cell-specific molecule 1
  Hs.154210             EDG1         Endothelial differentiation, sphingolipid G-protein-coupled receptor, 1
  Hs.122575             EDG4         Endothelial differentiation, lysophosphatidicacid G-protein-coupled receptor, 4
  Hs.468410             EPAS1        Endothelial PAS domain protein 1
  Hs.507621             FLT-1        Fms-related tyrosine kinase 1
  Hs.367725             GATA2        GATA binding protein 2
  Hs.201712             GLG1         Golgi apparatus protein 1
  Hs.509554             HIF1A        Hypoxia-inducible factor 1, alpha subunit
  Hs.515126             ICAM-1       Intercellular adhesion molecule 1 (CD54)
  Hs.150718             JAM3         Junctional adhesion molecule 3
  Hs.479756             KDR          Kinase insert domain receptor
  Hs.268107             MMRN1        Multimerin 1
  Hs.471200             NRP2         Neuropilin 2
  Hs.511603             NOS3         Nitric oxide synthase3
  Hs.514412             PECAM1       Platelet/endothelial cell adhesion molecule (CD31 antigen)
  Hs.405156             PPAP2B       Phosphatidic acid phosphatase type 2B
  Hs.252820             PGF          Placental growth factor, vascular endothelial growth factor-related protein
  Hs.82353              PROCR        Protein C receptor, endothelial (EPCR)
  Hs.89546              SELE         Selectin E (endothelial adhesion molecule 1)
  Hs.73800              SELP         Selectin P (granule membrane protein 140kDa, antigen CD62)
  Hs.514913             SERPINB2     Serine (or cysteine) proteinaseinhibitor, clade B (ovalbumin), member 2
  Hs.414795             SERPINE1     Serine (or cysteine) proteinaseinhibitor, clade E, member 1
  Hs.89640              TEK          TEK tyrosine kinase, endothelial
  Hs.50382              TJP2         Tight junction protein 2 (zona occludens 2)
  Hs.76090              TNFAIP1      Tumor necrosis factor, alpha-induced protein 1(endothelial)
  Hs.525607             TNFAIP2      Tumor necrosis factor, alpha-induced protein 2
  Hs.440848             VWF          Von Willebrand factor

Three HOC-EC and two HA-EC populations were investigated by Affymetrix GeneChip^®^Human Genome U95A Arrays. This list of highly expressed endothelial genes was extracted from the microarray results by keywords search within the complete probeset list annotated using SOURCE batch search (see Methods for details).

Genome wide transcriptional differences: tumor vs. normal tissue derived EC
---------------------------------------------------------------------------

Comparison of the transcriptional profiles of HOC-EC and HA-EC (experimental design and analyses detailed in Methods) showed that EC from tumor and normal tissue have distinct and characteristic expression patterns that are maintained *in vitro*. According to our selection criteria, 158 gene transcripts, corresponding to 179 probe sets, were more expressed by HOC-EC than by HA-EC. The genes belong to the different functional classes that are listed in Table [3](#T3){ref-type="table"}.

###### 

Transcriptional differences: tumor vs normal tissue derived EC

  **Unigene Cluster**                                    **Symbol**     **Gene Name**                                                                        
  ------------------------------------------------------ -------------- ------------------------------------------------------------------------------------ --
  **[Structural]{.ul}**                                  A                                                                                                   
  Hs.370287                                              ADAM23         A disintegrin and metalloproteinase domain 23                                        
  Hs.118127                                              ACTC           Actin, alpha, cardiac muscle                                                         
  Hs.533336                                              BAMBI          BMP and activin membrane-bound inhibitor homolog                                     
  Hs.489142                                              COL1A2         Collagen, type I, alpha 2                                                            
  Hs.443625                                              COL3A1         Collagen, type III, alpha 1                                                          
  Hs.210283                                              COL5A1         Collagen, type V, alpha 1                                                            
  Hs.211933                                              COL13A1        Collagen, type XIII, alpha 1                                                         
  Hs.409034                                              COL15A1        Collagen, type XV, alpha 1                                                           
  Hs.80552                                               DPT            Dermatopontin                                                                        
  Hs.412597                                              DSG2           Desmoglein 2                                                                         
  Hs.159291                                              DRP2           Dystrophin related protein 2                                                         
  Hs.371903                                              GYPE           Glycophorin E                                                                        
  Hs.190495                                              GPNMB          Glycoprotein (transmembrane) nmb                                                     
  Hs.328232                                              GPC1           Glypican 1                                                                           
  Hs.435557                                              KIF5C          Kinesin family member 5C                                                             
  Hs.436367                                              LAMA3          Laminin, alpha 3                                                                     
  Hs.519972                                              HLA-F          Major histocompatibility complex, class I, F                                         
  Hs.490874                                              MTX1           Metaxin 1                                                                            
  Hs.464469                                              MYOM1          Myomesin 1 (skelemin)                                                                
  Hs.504687                                              MYL9           Myosin, light polypeptide 9, regulatory                                              
  Hs.464829                                              CDH2           N-cadherin                                                                           
  Hs.116471                                              CDH11          OB-cadherin                                                                          
  Hs.487925                                              PDE4DIP        Phosphodiesterase 4D interacting protein (myomegalin)                                
  Hs.157818                                              KCNAB1         Potassium voltage-gated channel, shaker-related subfamily, beta member 1             
  Hs.407643                                              PCDH9          Protocadherin 9                                                                      
  Hs.106511                                              PCDH17         Hypothetical protein LOC144997                                                       
  Hs.7972                                                RIPX           Rap2 interacting protein x                                                           
  Hs.73800                                               SELP           Selectin P                                                                           
  Hs.468675                                              T1A-2          T1A-2 (lung type-I cell membrane-associated glycoprotein)                            
  Hs.143250                                              TNC            Tenascin C                                                                           
  Hs.371147                                              THBS2          Thrombospondin 2                                                                     
  Hs.443681                                              CSPG2          Versican                                                                             
  Hs.529901                                              XIST           X (inactive)-specific transcript                                                     
                                                                                                                                                             
  **[Enzymatic]{.ul}**                                   B                                                                                                   
  Hs.459538                                              ALDH1A3        Aldehyde dehydrogenase 1 family, member A3                                           
  Hs.421202                                              ABCA2          ATP-binding cassette, sub-family A (ABC1), member 2                                  
  Hs.489033                                              ABCB1          ATP-binding cassette, sub-family B (MDR/TAP), member 1                               
  Hs.646                                                 CPA3           Carboxypeptidase A3                                                                  
  Hs.75360                                               CPE            Carboxypeptidase E                                                                   
  Hs.252549                                              CTSZ           Cathepsin Z                                                                          
  Hs.154654                                              CYP1B1         Cytochrome P450, family 1, subfamily B, polypeptide 1                                
  Hs.516493                                              FAP            Fibroblast activation protein, alpha                                                 
  Hs.30332                                               GFPT2          Glutamine-fructose-6-phosphate transaminase 2                                        
  Hs.301961                                              GSTM1          Glutathione S-transferase M1                                                         
  Hs.470126                                              KYNU           Kynureninase (L-kynurenine hydrolase)                                                
  Hs.65436                                               LOXL1          Lysyl oxidase-like 1                                                                 
  Hs.307734                                              MME            Membrane metallo-endopeptidase                                                       
  Hs.478289                                              NLGN1          Neuroligin 1                                                                         
  Hs.30954                                               PMVK           Phosphomevalonate kinase                                                             
  Hs.77274                                               PLAU           Plasminogen activator, urokinase                                                     
  Hs.446429                                              PTGDS          Prostaglandin D2 synthase 21 kDa                                                     
  Hs.501280                                              PRSS11         Protease, serine, 11 (IGF binding)                                                   
  Hs.303090                                              PPP1R3C        Protein phosphatase 1, regulatory (inhibitor) subunit 3C                             
  Hs.128013                                              PRSS3          Protease, serine, 3                                                                  
  Hs.270279                                              TYRP1          Tyrosinase-related protein 1                                                         
  Hs.13225                                               B4GALT4        UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4                    
  Hs.69009                                               B3GNT3         UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3                        
                                                                                                                                                             
  **[Signaling]{.ul}**                                   C                                                                                                   
  Hs.143102                                              AB012943       Amine oxidase, copper containing 2                                                   
  Hs.167046                                              ADORA2B        Adenosine A2b receptor                                                               
  Hs.483909                                              ADMR           Adrenomedullin receptor                                                              
  Hs.132902                                              CAP2           CAP, adenylate cyclase-associated protein, 2 (yeast)                                 
  Hs.502328                                              CD44           CD44 antigen                                                                         
  Hs.78065                                               C7             Complement component 7                                                               
  Hs.473133                                              DOK5           Docking protein 5                                                                    
  Hs.523173                                              ENTPD1         Ectonucleoside triphosphate diphosphohydrolase 1                                     
  Hs.511899                                              EDN1           Endothelin 1                                                                         
  Hs.1407                                                EDN2           Endothelin 2                                                                         
  Hs.183713                                              EDNRA          Endothelin receptor type A                                                           
  Hs.481371                                              FAT            FAT tumor suppressor homolog 1 (Drosophila)                                          
  Hs.352                                                 FOLR3          Folate receptor 3 (gamma)                                                            
  Hs.432395                                              GPR39          G protein-coupled receptor 39                                                        
  Hs.79022                                               GEM            GTP binding protein overexpressed in skeletal muscle                                 
  Hs.198612                                              GPR51          G protein-coupled receptor 51                                                        
  Hs.156855                                              GABRG3         Gamma-aminobutyric acid (GABA) A receptor, gamma 3                                   
  Hs.167017                                              GABBR1         Gamma-aminobutyric acid (GABA) B receptor, 1                                         
  Hs.98262                                               GRIK2          Glutamate receptor, ionotropic, kainate 2                                            
  Hs.124161                                              HCN2           Hyperpolarization activated cyclic nucleotide-gated potassium channel 2              
  Hs.370984                                              IGSF4C         Immunoglobulin superfamily, member 4C                                                
  Hs.438102                                              IGFBP2         Insulin-like growth factor binding protein 2                                         
  Hs.369982                                              IGFBP5         Insulin-like growth factor binding protein 5                                         
  Hs.81134                                               IL1RN          Interleukin 1 receptor antagonist                                                    
  Hs.126256                                              IL1B           Interleukin 1, beta                                                                  
  Hs.129751                                              IL17R          Interleukin 17 receptor                                                              
  Hs.514535                                              LGALS3BP       Lectin, galactoside-binding, soluble, 3 binding protein                              
  Hs.125474                                              LPXN           Leupaxin                                                                             
  Hs.36566                                               LIMK1          LIM domain kinase 1                                                                  
  Hs.304475                                              LCP2           Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa)   
  Hs.418367                                              NMU            Neuromedin U                                                                         
  Hs.514556                                              NPTX1          Neuronal pentraxin I                                                                 
  Hs.8546                                                NOTCH3         Notch homolog 3 (Drosophila)                                                         
  Hs.434255                                              PSD3           Pleckstrin and Sec7 domain containing 3                                              
  Hs.506076                                              PTPRR          Protein tyrosine phosphatase, receptor type, R                                       
  Hs.436456                                              ROR1           Receptor tyrosine kinase-like orphan receptor 1                                      
  Hs.24950                                               RGS5           Regulator of G-protein signalling 5                                                  
  Hs.194691                                              RAI3           Retinoic acid induced 3                                                              
  Hs.95655                                               SECTM1         Secreted and transmembrane 1                                                         
  Hs.516726                                              SCG2           Secretogranin II (chromogranin C)                                                    
  Hs.156540                                              SGNE1          Secretory granule, neuroendocrine protein 1 (7B2 protein)                            
  Hs.75149                                               SH3GL2         SH3-domain GRB2-like 2                                                               
  Hs.444915                                              SLC1A1         Solute carrier family 1, member 1                                                    
  Hs.448520                                              SLC7A2         Solute carrier family 7, member 2                                                    
  Hs.351306                                              SLC16A4        Solute carrier family 16, member 4                                                   
  Hs.192686                                              SLC20A2        Solute carrier family 20, member 2                                                   
  Hs.12409                                               SST            Somatostatin                                                                         
  Hs.62886                                               SPARCL1        SPARC-like 1 (mast9, hevin)                                                          
  Hs.233160                                              STC2           Stanniocalcin 2                                                                      
  Hs.258326                                              LOC51760       Synaptotagmin 1                                                                      
  Hs.349470                                              SNCG           Synuclein, gamma                                                                     
  Hs.62192                                               TF             Tissue factor                                                                        
  Hs.534363                                              UCN            Urocortin                                                                            
  Hs.73793                                               VEGF           Vascular endothelial growth factor                                                   
  Hs.306251                                              ERBB3          V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)                    
                                                                                                                                                             
  **[Transcriptional factors and regulators]{.ul}**      D                                                                                                   
  Hs.65734                                               ARNTL          Aryl hydrocarbon receptor nuclear translocator-like                                  
  Hs.397705                                              CAMTA1         Calmodulin binding transcription activator 1                                         
  Hs.157002                                              DZIP1          DAZ interacting protein 1                                                            
  Hs.22634                                               ETV1           ets variant gene 1                                                                   
  Hs.155591                                              FOXF1          Forkhead box F1                                                                      
  Hs.519385                                              FOXD1          Forkhead related activator 4 (FREAC-4)                                               
  Hs.121443                                              HOP            Homeodomain-only protein                                                             
  Hs.180919                                              ID2            Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein               
  Hs.371013                                              JMJD2B         Jumonji domain containing 2B                                                         
  Hs.434284                                              LRRC17         Leucine rich repeat containing 17                                                    
  Hs.527007                                              MEOX2          Mesenchyme homeo box 2 (growth arrest-specific homeo box)                            
  Hs.89404                                               MSX2           Msh homeo box homolog 2 (Drosophila)                                                 
  Hs.1497                                                RARG           Retinoic acid receptor, gamma                                                        
  Hs.149261                                              RUNX1          Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)        
  Hs.465087                                              SMAD7          SMAD, mothers against DPP homolog 7 (Drosophila)                                     
  Hs.360174                                              SNAI2          Snail homolog 2 (Drosophila)                                                         
  Hs.89583                                               TLX1           T-cell leukemia, homeobox 1                                                          
  Hs.149991                                              THOC2          THO complex 2                                                                        
  Hs.125962                                              TFEC           Transcription factor EC                                                              
  Hs.1145                                                WT1            Wilms tumor 1                                                                        
  Hs.490510                                              ZNF212         Zinc finger protein 212                                                              
  Hs.22653                                               ZNF365         Zinc finger protein 365                                                              
  Hs.147765                                              ZNF415         Zinc finger protein 415                                                              
                                                                                                                                                             
  **[DNA replication, Cell Cycle and Apoptosis]{.ul}**   E                                                                                                   
  Hs.75823                                               AF1Q           ALL1-fused gene from chromosome 1q                                                   
  Hs.150749                                              BCL2           B-cell CLL/lymphoma 2                                                                
  Hs.122908                                              CDT1           DNA replication factor                                                               
  Hs.9999                                                EMP3           Epithelial membrane protein 3                                                        
  Hs.52903                                               8FSTL3         Follistatin-like 3 (secreted glycoprotein)                                           
  Hs.130853                                              HIST1H2BD      Histone 1, H2bd                                                                      
  Hs.534369                                              HIST1H2BE      Histone 1, H2be                                                                      
  Hs.152944                                              LOH11CR2A      Loss of heterozygosity, 11, chromosomal region 2, gene A                             
  Hs.432132                                              G0S2           Putative lymphocyte G0/G1 switch gene                                                
  Hs.514913                                              SERPINB2       Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2             
                                                                                                                                                             
  **[Others and unknown]{.ul}**                          F                                                                                                   
  Hs.441783                                              C14orf78       C14orf78                                                                             
  Hs.516956                                              C20orf91       chromosome 20 open reading frame 91 Hs.17936                                         
                                                         DKFZP434H132   DKFZP434H132 protein                                                                 
  Hs.132994                                              DKFZP434C171   DKFZP434C171 protein                                                                 
  Hs.41707                                               HSPB3          Heat shock 27 kDa protein 3                                                          
  Hs.432616                                              IMP-3          IGF-II mRNA-binding protein 3                                                        
  Hs.534372                                              INE1           Inactivation escape 1                                                                
  Hs.464563                                              KIAA0802       KIAA0802                                                                             
  Hs.65750                                               KIAA1086       KIAA1086                                                                             
  Hs.472010                                              PRNP           Prion protein (p27-30)                                                               
                                                         AC006276                                                                                            
                                                         U62317                                                                                              
                                                         W26626                                                                                              
                                                         W28546                                                                                              

List of the 158 gene transcipts more expressed by HOC-EC than HA-EC.

Three HOC-EC and two HA-EC populations were investigated by Affymetrix GeneChip^®^Human Genome U95A Arrays and analyzed searchingfor intrinsic differences, as described in Methods.

Microarray results reveal an alteration in cell-cell and cell-matrix interaction as shown by the enhanced expression of molecules such as desmoglein 2, N- and OB-cadherin, protocadherin-9 and -17 and P-selectin (Table [3A](#T3){ref-type="table"}). In keeping with the notion that the extracellular matrix in tumor differs from that in normal tissue \[[@B22]\] glypican-1, laminin alpha 3, tenascin C, versican, as well as different types of collagens (collagen typeI-alpha2, typeIII-alpha1, typeV-alpha1, typeXIII-alpha1 and typeXV-alpha1) and thrombospondin-2, were expressed at higher levels by HOC-EC than by HA-EC (Table [3A](#T3){ref-type="table"}). Moreover, alterations of cytoskeletal protein involved in cell motility, for instance the actin and myosin related molecules MYOM1, MYL9 and RIPX, were also observed (Table [3A](#T3){ref-type="table"}).

The peptidase family is the most represented among the enzymatic classes of genes expressed by HOC-EC (Table [3B](#T3){ref-type="table"}). It includes carboxypeptidase A3, carboxypeptidase E, cathepsin Z, membrane metallo-endopeptidase, serinprotease 11, and urokinase-plasminogen activator. This is consistent with the concept that peptidases are very important for the activation of pro-enzymes or protein precursors, as well as in the degradation of the extracellular matrix \[[@B23]\].

Most of the listed genes are involved in signaling and comprise molecules previously shown to be involved in angiogenesis and other vascular functions, such as adrenomedullin receptor, CD44, endothelin-1 and -2, endothelin receptor-A and tissue factor (Table [3C](#T3){ref-type="table"}).

Consistent with the notion that the vascular and nervous systems share similar signals and principles \[[@B24]\], 3 members of the GABA receptors family and several molecules involved in synaptic signaling, as well as elements involved in brain differentiation and axon elongation, were expressed at higher levels by HOC-EC (Table [3C](#T3){ref-type="table"}).

Four members of the Solute Carrier Family (SLC1A1, SLC7A2, SLC16A4, SLC20A2) were over-expressed in HOC-EC, suggesting an alteration in the extra-intracellular exchange of metabolites (Table [3C](#T3){ref-type="table"}). Among the transporters, the enhanced expression of the ATP-binding cassette family members ABCA2 and ABCB1 (Table [3B](#T3){ref-type="table"}) should be emphasized. ABCB1, best known as MDR/p-glycoprotein, is involved in drug removal from cells.

Higher expression also affected genes involved in transcriptional response, such as members of the zinc finger protein family (DZIP1, JMJD2B, SNAI2, WT1, ZNF212, ZNF365, ZNF415) and of the homeobox family (HOP, MEOX2, MSX2, TLX1) (Table [3D](#T3){ref-type="table"}).

SMAD7 (Table [3D](#T3){ref-type="table"}) and BAMBI (Table [3A](#T3){ref-type="table"}), involved and acting as inhibitors of TGF-beta signaling, were also more expressed.

Among the class of cell cycle regulators, the high expression of the anti-apoptotic protein BCL2 is noteworthy (Table [3E](#T3){ref-type="table"}).

Selected transcripts are expressed by tumor derived endothelial cells
---------------------------------------------------------------------

In order to identify novel markers of tumor endothelium our attention focused on transcripts that are highly expressed by tumor-derived endothelium (i.e., HOC-EC), but whose products and functions were not previously reported as being involved in tumor angiogenesis or associated to vascular functions. Among them we distinguished four genes on the basis of their structural or functional characteristics, such as the presence of transmembrane domains and/or enzymatic activities: disintegrin and metalloproteinase domain 23 (ADAM23), fibroblast activation protein alpha (FAP), transmembrane glycoprotein nmb (GPNMB), and serine protease 3 or mesotrypsin (PRSS3). The relative expression in HOC-EC compared to HA-EC was 2.6 for ADAM23, 4.1 for FAP, 4.6 for GPNMB and 2.5 for PRSS3, as calculated from microarray data. These results were validated by real-time PCR in EC isolated from six neoplastic tissues (five ovarian and one kidney carcinoma specimens) and from four non-neoplastic tissues (three adrenal glands and one skin specimen) different from those investigated by microarray. These tumor or normal tissue derived EC are described in Table [1](#T1){ref-type="table"}.

To mimic the different environments in which EC might be embedded *in vivo*-- either subjected to persistent stimulation imposed by the tumor cells or not, EC were investigated both in the presence (Figure [1A](#F1){ref-type="fig"}) or the absence (Figure [1B](#F1){ref-type="fig"}) of the angiogenic factors VEGF, FGF- 2, of epidermal growth factor (EGF) and of fibronectin. Under both conditions the expression of ADAM23, FAP, GPNMB and PRSS3 genes was much higher in EC isolated from tumor specimens, as shown by the fold difference values (Figures [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). As specified by the p values, statistical analysis demonstrated a significant disparity in the expression levels for each of the genes being investigated (Figures [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}).

![**Real-time PCR quantification of gene expression in endothelial cells isolated from human cancer and normal tissue specimens**. Endothelial cells were exposed (A) or not (B) to VEGF, EGF, FGF-2 and fibronectin (see Methods for details). Fold differences for each EC population and p values for each gene analyzed are shown. The expression of the target gene was normalized to 18s rRNA for each of the EC populations being evaluated: ΔCt = Ct~target~- Ct~18s~. Statistical analysis on ΔCt values was performed comparing tumor and normal tissue derived EC. Fold differences were calculated according to the comparative ΔΔCt method: Fold difference = 2 ^-(ΔCt\ each\ population-ΔCt\ ref)^by arbitrarily considering the normal tissue derived ECs as reference (ΔCt~ref~being their average ΔCt value).](1471-2164-9-201-1){#F1}

These results confirm microarray findings and demonstrate that such a diversity is indeed an intrinsic characteristic associated to the tumor or normal tissue origin of the EC, regardless of the culture conditions. Sarcoglycan epsilon (SCGE), chosen as an internal control of a gene expressed to a much lesser extent by HOC-EC, confirmed the microarray results (Figures [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}).

Expression in non endothelial cells
-----------------------------------

Having shown that ADAM23, FAP, GPNMB, and PRSS3 were expressed by a panel of EC, with the highest expression found in TdEC, we next investigated their expression in other cell types. The gene expression analysis revealed that they could be expressed to different extents also by other stromal cells, such as fibroblasts (HuFb and Malme3) and smooth muscle cells (UASMC), but in general not by tumor cells (Figure [2](#F2){ref-type="fig"}). Specifically, their expression in the carcinoma cell lines (1A9 and SKOV3 ovarian, MDA-MB-431 breast and HT29 colon) was not or was barely detectable (with the exception of PRSS3 by the HT29 colon carcinoma) (Figure [2](#F2){ref-type="fig"}). This lack of expression was supported by the Northern Blot results of a panel of tumor cell lines represented on the Multiple Tissue Expression array (Figure [3](#F3){ref-type="fig"}). Moreover, the Reference database for gene Expression Analysis (RefExA \[[@B25]\]) confirmed that the tumor cell lines did not show expression of the selected genes.

![**Gene expression in different cell lines**. Levels of expression of ADAM23, FAP, GPNMB and PRSS3 were evaluated in fibroblasts (HuFb and Malme3) and smooth muscle cells (USMAC) as well as in tumor cell lines (1A9, SKOV3, HT29 and MDA-MB-231). Gene expression of each target gene was normalized to 18s rRNA for each cell type (ΔCt = Ct~target~- Ct~18s~). Average of ΔCt of the target gene from tumor derived ECs (Figure 1) was assumed as reference (ΔCt~ref~). Fold differences for each cell type were calculated according to the comparative ΔΔCt method (Fold difference = 2^-(ΔCt\ each\ celltype-ΔCt\ ref)^) and expressed as percentage relative to tumor-derived EC (100%).](1471-2164-9-201-2){#F2}

![**Tissue expression of ADAM23 and GPNMB**. ADAM23 and GPNMB expression were evaluated by Multiple Tissue Expression array. The membrane, comprising polyA+ mRNA from different adult and fetal tissues, was hybridized with a ^32^P labeled probe specific for the two genes and hybridization visualized by autoradiography. Bars represent the optical density evaluated for each dot.](1471-2164-9-201-3){#F3}

Conversely, the expression of FAP and GPNMB was higher in both the HuFb and MALME 3 fibroblasts than in EC, and FAP was also expressed at a higher level by the UASMC smooth muscle cells. ADAM23 and PRSS3 were instead expressed to a lesser extent by all the stromal cells analyzed (Figure [2](#F2){ref-type="fig"}).

Expression in healthy tissues
-----------------------------

Tissue expression of ADAM23 and GPNMB was assessed using a Multiple Tissue Expression (MTE) array: a panel of human mRNAs in dot-blot format from 58 normal adult tissues, seven fetal tissues, and eight cell lines. As shown in Figure [3](#F3){ref-type="fig"}, ADAM23 and GPNMB were expressed by a limited subset of tissues, while tumor cells did not express either one of them. In particular, ADAM23 expression was highest in cardiovascular tissues and fetal heart, as well as in central nervous system (CNS) samples, while it was much lower in fetal brain (Figure [3](#F3){ref-type="fig"}). The expression of GPNMB was highest in cardiovascular tissues and fetal heart, as well as in placenta, while it was detected to a much lesser extent in lung, uterus, and bladder tissue. (Figure [3](#F3){ref-type="fig"}). These Northern Blot results for ADAM23 and GPNMB expression were confirmed by the RefExA database \[[@B25]\].

Data from RefExA \[[@B25]\] and literature report the expression of PRSS3 by brain, colon and pancreas \[[@B26]\], while FAP expression is described only in the activated stromal fibroblast of tumors \[[@B27]\].

Expression by tumor vasculature in vivo
---------------------------------------

In order to investigate the *in vivo*localization of ADAM23, GPNMB and PRSS3, human tumor tissues were analyzed by *in situ*hybridization.

Endothelial expression of the selected genes was confirmed in the tumor samples analyzed. As shown in Figure [4](#F4){ref-type="fig"}, the hybridization signals for ADAM23, GPNMB, and PRSS3 localized around the blood vessels, and exclusively in the vascular walls. According to the *in vitro*results, tumor cells did not express the transcripts, as shown by the absence of staining in the parenchyma of the tissues (Figure [4A, B, C](#F4){ref-type="fig"}). Noteworthy was the finding that stromal compartments (except for the blood vessels) lacked the expression of either gene.

![***In situ*hybridization of human tissues**. Shown are representative samples of medulloblastoma (A), brain metastasis of an adenocarcinoma (B) and Ewing sarcoma (C), hybridized with antisense probes for ADAM23, GPNMB and PRSS3, respectively. Positively stained blood vessels are indicated by arrows. Related hybridization with control sense probes for ADAM23, GPNMB and PRSS3 is shown in panel D-E-F. Normal brain samples, from different donors, hybridized respectively with antisense probes for ADAM23 (G) and GPNMB (H) are shown. Alzheimer\'s-diseased brain hybridized with antisense probe for PRSS3 is shown (I).](1471-2164-9-201-4){#F4}

No staining was observed in normal brain and Alzheimer\'s-diseased brain (Figures [4G, H, I](#F4){ref-type="fig"}). It is remarkable that ADAM23 and PRSS3 transcripts, whose expression in CNS was revealed by the MTE array and/or reported by RefExA \[[@B25]\], were not detected in normal or diseased brain, except for blood vessels in medulloblastoma or metastatic adenocarcinoma (Figure [4](#F4){ref-type="fig"} and data not shown).

Sense probes did not hybridize with any of the tissue sections analyzed (Figures [4D, E, F](#F4){ref-type="fig"}).

Discussion
==========

Targeting the process of tumor neovascularization has become a promising anti-cancer strategy. This is particularly evident when vascular targeting agents are combined with conventional chemotherapy and radiotherapy, as demonstrated by recent reports and clinical trials \[[@B28]\]. However, the success of this approach depends on the availability of suitable endothelial markers that can be used to selectively target the tumor vascular compartment or to deliver a ligand-directed effector to the endothelium \[[@B7]\]. Herein, we successfully combined a method to isolate and culture endothelial cells (EC) from human specimens of tumor (TdEC) and non-neoplastic (NdEC) origin with oligonucleotide microarray analysis to compare their gene expression. We first showed that the TdEC transcriptional profile differs from that of NdEC, and, thereafter identified specific molecular features of tumor-derived endothelium.

Our laboratory previously established a procedure \[[@B29]\] to derive EC of high purity from human specimens, their origin assessed by immunohistochemical staining for the three endothelial markers CD31/PECAM-1, VE-cadherin and vWF. Accordingly, microarray results confirmed their expression, but also revealed the expression of many other genes annotated as typically endothelial through SOURCE \[[@B30]\]. These included E-selectin, VEGFR-1, and VEGFR-2, further confirming our previous findings \[[@B21]\]. Despite being less successful with tumors (e.g., a 50% success rate out of 18 ovarian carcinoma specimens) than with non neoplastic (a 90% success rate for adrenal gland), the reproducible yield of EC from human specimens enabled us to explore molecular differences between tumor and normal endothelium.

The comparative transcriptomic analysis of EC from ovarian carcinoma (HOC-EC) and adrenal gland (HA-EC) revealed the higher expression of 158 gene transcripts by HOC-EC. The finding that tumor and normal tissue EC have distinct gene expression patterns concurs with other investigations, which describe genes that are preferentially expressed by endothelium from malignant cancer \[[@B12]-[@B15]\]. In these studies, SAGE \[[@B12]-[@B14]\] or microarray analyses \[[@B15]\] were executed on EC freshly obtained by immunoselection of *ex vivo*tissue samples. Endothelial cells in culture often lose their tissue-specificity and their specialized properties \[[@B31]\]. Our results, nonetheless, demonstrate that we were able to preserve *in vitro*some of the phenotypes that distinguish the diverse endothelia. Likewise, they confirm our previous findings \[[@B21]\] and agree with other reports \[[@B32],[@B33]\] showing that, despite being in culture, EC isolated from different vascular beds possess characteristic gene expression profiles.

Here we describe for the first time a much higher expression of ADAM23, FAP, GNPNB and PRSS3 in EC derived from six tumor samples than in EC from four normal tissue specimens examined by real-time PCR, whose origin differed from that investigated by microarray analysis. The differences we detected between TdEC and NdEC were maintained whether or not they were exposed to a combination of pro-angiogenic factors that presumably mimic the different environmental conditions under which EC might be embedded *in vivo*(that is, subjected or not to persistent stimulation imposed by the tumor cells, as in the case of blood vessels in adult normal tissues). These results suggest that the transcriptional differences are not culture condition artifacts, but, rather, true differences that distinguish EC of different origin (i.e., tumor vs. normal).

Despite having mainly utilized EC from ovarian cancer and from adrenal glands as the non-neoplastic counterpart, the results hold true for EC isolated from kidney cancer and skin specimens (even though only one EC population could be analyzed). These observations, would seem to indicate that the EC characteristics we observed are not organ-specific, but, rather, exclusive of TdEC. This is in agreement with a recent report \[[@B15]\] that compared EC freshly isolated from ovarian cancer and normal ovary in which several of the genes identified as distinctive of the tumor associated vasculature showed conserved expression across the EC from other tumor types, such as colon \[[@B12]\], brain \[[@B13]\] and breast \[[@B14]\].

Cultures of EC are valuable tools for biochemical and functional analysis, but they do not reflect the physiological situation entirely. All the information should be considered critically from the standpoint of what might occur in blood vessels *in vivo*. To this end, *in situ*hybridization results confirmed ADAM23, GNPNB and PRSS3 expression associated to blood vessels in tumor tissues, but the lack of their expression in cancer cells (as well as in normal tissue).

Overall, these findings support the premise that endothelial markers identified *in vitro*are likely to have *in vivo*relevance, and bear out the validity of our experimental setting designed to reproduce situations that might occur *in vivo*.

ADAM23 belongs to the cellular disintegrins, a family of membrane-anchored proteins that are potential regulators of cell-to-cell and cell-to-matrix interactions \[[@B34]\] and for which a specific binding interaction with alphaVbeta3 integrin has been demonstrated \[[@B35]\]. Our MTE array results showed that ADAM23 is expressed in fetal and adult heart, and also confirmed its previously reported expression by fetal and adult brain \[[@B34],[@B35]\]. However, our *in situ*hybridization finding (lack of gene expression in normal or Alzheimer\'s-diseased brain) contradicted the latter, which implies that the expression of ADAM23 might indeed be much higher in tumor EC, including blood vessels in medulloblastoma, a highly malignant brain tumor, than in the brain. Further studies, aimed to produce antibodies to ADAM23, are necessary to prove its suitability as a tumor vascular target. Our results also revealed that ADAM23 was not expressed in cancer cells. This observation is consistent with the data available from RefExA and other recent reports \[[@B36]\], which describe hypermethylation of the ADAM23 promoter that silences its expression in breast and pancreatic cell lines and in the corresponding primary tumors. Our evidence of a high expression of ADAM23 by TdEC suggests that this protein might be important for establishing contacts and promoting adhesive functions during the pathological processes leading to the formation of new blood vessels within the tumor. In addition, it is intriguing to speculate that this protein -- through its ability to bind alphaVbeta3 -- could play some specialized role in the maintenance of vascular functions within the tumor. In keeping with this hypothesis is the fact that alphaVbeta3 is expressed by EC and has been shown to be involved in tumor neo-vascularization \[[@B37]\].

GPNMB is a type I membrane protein identical to the hematopoietic growth factor inducible neurokinin-1 type (HGFIN) \[[@B38]\] sharing similarities with neurokinin-1 (NK1), a receptor for tachykinins and a member of seven transmembrane G protein coupled receptors. HGFIN was shown to interact with Substance P (SP), which has been reported to induce EC proliferation and increase vascular density in an *in vivo*model of inflammation, and these effects could be inhibited by an NK1 receptor antagonist \[[@B39]\]. The action of SP via the NK1 receptor may be a direct effect, since NK1 receptors have previously been localized to endothelium \[[@B40]\], and both SP and selective NK1 agonists were shown to enhance *in vitro*EC proliferation \[[@B41]\]. Substance P *in vivo*also contributes to vascular permeability, plasma extravasation, and edema \[[@B42]\], all features that characterize the abnormal vasculature of tumors. Our evidence of a high expression of GPNMB by TdEC suggests that GPNMB may be a tumor stroma receptor for SP, involved in tumor angiogenic events and in determining the distinctive features of tumor vasculature. Corroborating this premise are data suggesting that, in addition to NK1 receptors, other mechanisms contribute in mediating *in vivo*SP effects on EC \[[@B39]\].

The PRSS3 gene encodes for a trypsinogen whose functions have not yet been fully elucidated \[[@B43]\]. PRSS3 transcript, whose expression in CNS is reported by RefExA, was not detected in normal or Alzheimer\'s-diseased brain, except for blood vessels in a brain metastasis. This finding might mean that the expression of PRSS3 is indeed characteristic of tumor EC, as seen for ADAM23. Our search in the RefExA and SOURCE databases revealed that PRSS3 was not expressed by tumor cells, with the exception of colon carcinoma. It seems very plausible that PRSS3 produced by TdEC may contribute to tumor angiogenesis, invasion and metastasis through its peptidase activity. This notion upholds evidence that the migration and invasion of EC in the tumor tissue requires the activation of pro-enzymes (such as pro-metalloproteinases) and protein precursors \[[@B44]\]. To this end, it is noteworthy that other peptidases (including urokinase-plasminogen activator \[uPA\] and FAP) were among the genes we found to be highly expressed by tumor-derived endothelium. In particular, uPA is capable of initiating the process of extracellular matrix degradation through the activation of plasminogen and matrix metalloproteases; in addition, it has been shown to be required for the migration of EC during the process of angiogenesis \[[@B45]\]. It is interesting that the expression of the uPA receptor (uPAR) was also seen to be higher in HOC-EC than in HA-EC (C. Ghilardi unpublished observation), a finding that would implicate the uPA-uPAR system in tumor driven angiogenesis.

Our results show that the cell surface protease FAP was also expressed at significantly higher levels by TdEC than by normal EC. FAP was originally reported to be an antigen recognized by F19 antibody in cultured fibroblasts \[[@B27]\]. Accordingly, its expression in our tests was found to be much higher in cultured fibroblasts (HuFb and MALME3) and in smooth muscle cells (UASMC). Nonetheless, while normal adult tissues are generally FAP-negative, its expression is detectable in the stroma of over 90% of carcinomas \[[@B27]\]. Such behavior suggested its suitability for stromal targeting and/or cancer detection and therapy, and in recent years has underpinned the development of a humanized anti-FAP antibody (sibrotuzumab) and the implementation of clinical trials \[[@B46]\]. Our results uphold the notion that FAP is a valid target for therapy, be it as stromal or as vascular marker. In keeping with our results, the *in vivo*expression of FAP on blood vessels was recently demonstrated by Ghersi et al. in invasive breast ductal carcinoma \[[@B47]\].

Many of the transcripts we found to be expressed at a high level by EC from neoplastic tissues were previously reported as being involved in tumor angiogenesis or expressed by tumor EC. In this regard, it is worth listing the various types of matrix proteins that we detected, namely: collagens alpha-2 type I, alpha-1 type III, V, XIII and XV, glypican-1, laminin alpha3, and tenascin C. Our results confirm similar findings from other laboratories \[[@B12],[@B13],[@B15]\] and denote a remodeling of the extracellular matrix known to promote blood vessel sprouting and growth. In keeping with the experimental data, and as an example, tenascin C was shown to be expressed *in vivo*and to colocalize with microvessels in the stroma of non-small cell lung cancer \[[@B48]\].

The expression of cell adhesion proteins was also altered in TdEC. This may be explained by the fact that migrating and proliferating EC must \"loosen up\", that is, detach and then create new interactions. Our results implicate CD44 and cadherins in this process, and confirm previous reports showing N-cadherin over-expression on proliferative state EC \[[@B49]\], and enhanced expression of CD44 on the vasculature of solid tumors compared to normal tissue \[[@B50]\]. Noteworthy is the finding that CD44 expression was up-regulated when the TdEC were exposed to angiogenic growth factors (C. Ghilardi unpublished observations), in accordance with previous results showing that FGF-2 and VEGF stimulate CD44 expression in EC \[[@B50]\].

Interestingly, ABCA2 and ABCB1 (MDR-1/p-glycoprotein 1) were also more abundantly expressed by TdEC, reflecting the previously reported higher expression of p-glycoprotein 1 in EC from glioma than from normal brain \[[@B51]\]. The ATP-binding cassette transporters (ABC) are responsible for the efflux of chemotherapeutic agents in cancer cells \[[@B52]\]. These data suggest that the multidrug resistance phenomenon in tumors may be due to both EC and tumor cells.

Molecules such as SMAD7, BAMBI and BCL2 are listed among the transcripts that are more highly expressed by HOC-EC than by HA-EC. SMAD7 and BAMBI interfere with the TGFβ pathway and may potentially block the anti-proliferative action of TGFβ \[[@B53]\]. Their expression may induce an enhanced proliferation of the TdEC, which is one of the steps of the angiogenic process. BCL2 is one of the most widely recognized anti-apoptotic factors, whose upregulation enhances EC survival and intratumoral angiogenesis, thus promoting tumor growth \[[@B54]\].

Emerging studies suggest that the vascular and the nervous systems share the same molecular signals in their development. The involvement of netrins, semaphorins, Robo/Slit and VEGF families in both angiogenesis and neurogenesis has been demonstrated in recent years \[[@B24]\]. In keeping with these findings, our results revealed that TdEC express numerous molecules that are associated with the CNS or are implicated in brain differentiation and axon guidance. In particular, ADORA2B was identified as a novel netrin-1 receptor and reported to mediate axon outgrowth \[[@B55]\]. In a similar way -- and considering that netrin-1 is pro-angiogenic \[[@B56]\] -- our results allow speculatation that ADORA2B could mediate the sprouting of vessels during tumor neovascularization.

Conclusion
==========

Targeting angiogenesis and vasculature represents a promising option to control tumor growth and dissemination. To exploit this opportunity, however, selective targets in tumor associated vasculature need to be identified.

We describe a model consisting of *in vitro*cultured endothelial cells isolated from human normal and neoplastic specimens that maintained their respective molecular phenotype and enabled us to determine molecular differences between tumor and normal tissue derived EC. Specifically, we identified four transcripts whose expression is much higher in endothelial cells from tumors than from normal tissue. The *in vivo*expression in cancer-associated blood vessels was confirmed by *in situ*hybridization of human specimens.

This work evinces some of the distinctive features of tumor-derived endothelium, and identifies potential markers that may provide the groundwork for novel therapeutic strategies. Future studies are needed to clarify the functions and roles of these molecules in tumor progression and vascularization.

Methods
=======

Isolation, culture and characterization of endothelial cells (EC)
-----------------------------------------------------------------

The method for isolation of EC has been described in detail by \[[@B29],[@B21]\]. Briefly, tissue specimens were digested by type I collagenase (EC 3.4.24.3 -- clostridiopeptidase A, Sigma-Aldrich, St. Louis MO, USA -- Milan, Italy) and the suspension plated. Six to 10 days later, the EC were positively purified using anti-CD31 antibody-coated magnetic beads, seeded and cultured as detailed in the supplementary information \[see Additional file [1](#S1){ref-type="supplementary-material"}\].

Human umbilical vein EC (HUVEC) were obtained following the procedure described by Jaffe \[[@B57]\] and cultured as detailed in \[[@B58]\].

To confirm their endothelial origin, EC cultures were analyzed by immunohistochemical methods to evaluate the expression of von Willebrand Factor (vWF), platelet-endothelial cell adhesion molecule-1 (CD31/PECAM-1), Vascular E-cadherin (VE-cadherin), and alpha-smooth muscle Actin (alpha-SMA), and by fluorescence activated cell sorter (FACS) to evaluate low-density lipoprotein (LDL) uptake and CD31/PECAM-1 antigen expression, as previously described \[[@B21]\].

Cell cultures
-------------

HT29 colon carcinoma cells (ATCC-American Type Culture Collection) were grown in minimum essential medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS).

1A9 (a subclone of the A2780 cell line \[[@B59]\]) and SKOV3 human ovarian carcinoma cells, MDA-MB-231 human breast carcinoma cells, and HuFb and Malme-3 human fibroblasts (all from ATCC) were grown in RPMI-1640 medium plus 10% FBS.

Umbilical artery smooth muscle cells (UASMC) were purchased from Clonetics (Clonetics-BioWhittaker, Walkersville MD, USA -- Caravaggio BG, Italy) and cultured following the manufacturer\'s protocol in SmBM Growth Medium.

RNA isolation
-------------

Total RNA was isolated from cultured cells using Trizol^®^(GIBCO-Invitrogen) or RNeasy Mini Kit (Qiagen, Maryland, USA) following the manufacturer\'s protocols. Potential genomic DNA contaminations were removed by DNAse (Ambion, Austin, USA) treatment followed by RNA CleanUp with RNeasy Mini Kit. The purity and integrity of the RNA was checked by gel electrophoresis, and concentration was determined spettrophotometrically.

Genome wide analysis of gene expression by microarray
-----------------------------------------------------

### Transcriptional difference: HOC-EC vs. HA-EC

We are aware that culture conditions alter gene expression. To this end, all the EC under investigation were analyzed under two different conditions: either seeded onto type I collagen coated tissue culture plastic (BioCoat-Becton Dickinson, Bedford MA, USA) in endothelial cell basal medium (EBM -- Clonetics-BioWhittaker, Walkersville MD, USA) plus 5% FBS or onto BioCoat plasticware additionally coated with 1 μg/cm^2^fibronectin (Plasma Fibronectin, BD-Biosciences, Bedford MA, USA) in EBM plus 5% FBS supplemented with and 10 ng/ml Epidermal Growth Factor (EGF), 10 ng/ml Vascular Endothelial Growth Factor (VEGF), 2 ng/ml Fibroblast Growth Factor (FGF-2) (all from R&D System, Minneapolis MN, USA); from here on respectively called \"unexposed\" or \"exposed\" to a tumor/angiogenic environment.

To maximize the likelihood of detecting the intrinsic differences between HOC-EC and HA-EC by minimizing the influence of the artificial environment upon them, we opted to select only those genes that were differentially expressed regardless of the culture conditions.

#### Microarray analysis

GeneChip^®^Human Genome U95A Arrays (Affymetrix UK Ltd, High Wycombe, UK) that monitor the expression of approximately 12,000 genes were utilized to analyze the transcriptional profiles of 3 independent HOC-EC together with 2 HA-EC populations, under both \"exposed\" and \"unexposed\" culture conditions. Raw Affymetrix data were then processed for each of the 10 GeneChip^®^arrays.

#### Data analysis

For each probeset, the mean of the average difference values for the two \"exposed\" HA-EC samples was calculated only if both were greater than 20 arbitrary units. Similarly, the mean of at least two average difference values for the three \"exposed\" HOC-EC samples was calculated only if each of them was greater than 20 arbitrary units. The same was done for the \"unexposed\" samples. Then, the log2 of the HOC-EC versus HA-EC ratios was calculated only for the probesets having both means available. Probesets with log-ratios greater than 1.3 (corresponding to a fold change of 2.5) for both \"exposed\" and \"unexposed\" samples were considered. Such a threshold was obtained by fitting the distributions of the \"exposed\" and \"unexposed\" log2-ratios with a normal distribution and calculating upper bound of the 99% confidence interval.

#### Gene annotation

the probesets expressed to a greater extent in HOC-EC than in HA-EC were divided into functional classes using the publicly available Est Annotation and the Keyword Clustering Machines \[[@B60]\] and were then manually checked.

### Typical endothelial genes: HOC-EC and HA-EC

Endothelial markers represented on the Affymetrix GeneChip^®^were found by keyword search within the complete probeset list annotated using the publicly available SOURCE batch search \[[@B30],[@B61]\]. The mean of average difference values for each transcript in HOC-EC and HA-EC was calculated. Genes with the mean value greater than 500 were included in the list of expressed endothelial markers shown in Table [2](#T2){ref-type="table"}.

Additional information on gene expression was obtained from the publicly available Reference database for gene Expression Analysis (RefExA) of the Laboratory for System Biology and Medicine (LSBM) (RCAST, University of Tokyo) \[[@B25]\].

Quantitative real-time PCR
--------------------------

Two micrograms of total cellular RNA were reverse transcribed (RT) using the Taqman Reverse Transcription Reagents and Random Hexamer primers (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s protocols. To check for DNA contamination, a control RT reaction was set up for each sample without the addition of reverse transcriptase.

Quantitative real-time PCR was performed in 25 μl-reactions on the GeneAmp 5700 Sequence Detection System (Applied Biosystems) using either SYBR Green or TaqMan chemistry. Primer sets for PCR amplifications are listed in supplementary table 1 \[see Additional file [1](#S1){ref-type="supplementary-material"}\] and were designed using the Primer Express 1.5 software (Applied Biosystems) and synthesized by Gibco-Life Technologies. Primer concentration was 200 nM for all SYBR Green assays, except for 18s rRNA assay (50 nM); dissociation curves were routinely performed. For transcripts analyzed with TaqMan chemistry, specific Assay-on-Demands were purchased from Applied Biosystems \[see supplementary table 1 in Additional file [1](#S1){ref-type="supplementary-material"}\].

All assays were performed using duplicate samples of each cDNA synthesis. Reverse transcription reactions and real-time PCR analyses were carried out at least twice for each gene transcript to determine consistency of results.

Gene expression of all transcripts was normalized to the endogenous control gene human 18s rRNA and for each population the ΔCt value was calculated (ΔCt = Ct~targetgene~- Ct ~18s~). Statistical analysis with Student\'s t-test (unpaired) on ΔCt values was performed to compare the expression levels of target genes in EC samples from normal and neoplastic tissues.

Fold differences were calculated according to the comparative ΔΔCt method (GeneAmp 5700 SDS User\'s Bulletin; Applied Biosystems).

Northern Blot
-------------

For the analysis of tissue distribution, the MTE Array 2 (Clontech, Palo Alto CA, USA) was hybridized following manufacturer\'s instructions. Briefly, the filter was pre-hybridized for 30 min at 65°C with ExpressHyb (Clontech). Hybridization was carried out O.N. at 65°C in ExpressHyb containing 130 μg/ml fish sperm DNA, 6 μg/ml Cot -1 DNA and the ^32^P-labeled cDNA probe. Filter was washed with SSC2x/SDS0.1% at 65°C, followed by washes at 55°C with SSC0.1x/SDS 0.5%. Because the panel of human mRNAs loaded onto the MTE Arrays in dot-blot format are normalized using eight different housekeeping genes, the hybridization results can be attributed to actual differences in target mRNA abundance.

Densitometric analysis of the dots was performed with Gel-Pro Analyzer Software (Media Cybernetics, Silver Spring, MD). Optical Density (OD) values are reported in Figure [3](#F3){ref-type="fig"}.

cDNA probe for ADAM23 corresponding to nt 2241--2743 of GeneBank:NM_003812, and cDNA probe for GPNMB corresponding to nt 416--984 of GeneBank:NM_002510 were PCR amplified and gel purified.

*In situ*hybridization
----------------------

*In situ*hybridization experiments were carried out with a mixture of specific biotin-labeled oligonucleotide antisense (or sense) probes for ADAM23, GPNMB and PRSS3 (Metabion International AG, Martinsried, Germany) listed in the supplementary Table 2 \[see Additional file [1](#S1){ref-type="supplementary-material"}\]. Human cancer specimens, such as adenocarcinoma brain metastasis, angioma from a Von Hippel Lindau disease patient, Ewing sarcoma, and medulloblastoma, were analyzed along with normal brain and Alzheimer\'s-diseased brain.

After removal of paraffin, the tissue sections were rehydrated and heat-treated in 0.1 M sodium citrate (pH = 6), washed for 5 min with water and then with 2× SSC, and air dried. Sections were allowed to hybridize overnight at room temperature in 15% formamide, 5× SSC, 10% dextran sulphate, 1× Denhardt\'s solution (0.02% Ficoll400, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin) and 400 μg/ml fish sperm DNA. Probe concentration was 10 nM for each oligonucleotide (corresponding to 10 fmol/μl). Approximately 100 μl of hybridization solution was applied to each slide.

After hybridization, sections were washed for 15 min in 2× SSC and for 10 min in water at room temperature. They were rinsed three times in PBS/0.1% Triton, and incubated for 20 min with blocking buffer (PBS/0.1% Triton, 5% FCS). Bound probes were detected using a mouse anti-biotin antibody (DakoCytomation, Glostrup, Denmark). Amplification of the signal was achieved with the Vectastain elite ABC Kit (Vector Laboratories, Burlingame, CA) according to the manufacturer\'s protocol. Colorimetric detection was completed with the AEC Substrate kit (Vector Laboratories). Finally, the tissue sections were counterstained with hematoxylin and embedded on an aqueous mounting medium.

Ethical consent
---------------

Endothelial cells have been isolated from biopsies collected at the San Gerardo Hospital (Monza, Italy) from patients undergoing therapeutic surgery from September 1998 to March 2004. The collection and use of the tissue samples was approved by the Local Scientific Ethical Committee in compliance with the principles enunciated in the Helsinki Declaration \[[@B62]\]. Tissue samples (including tumors) used for in situ hybridization were acquired from the Oxford based Thomas Willis brain bank. The collection of the tissues was done in accordance with the requirements of the Human Tissue Act, with full informed consent of participants and relatives. Ethical approval for research to be conducted on the tissues was granted by COREC (No: 1656).
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